CLINICAL CASE OF COVID-ASSOCIATED GUILLAIN-BARRE SYNDROME
ARTICLE PDF (Українська)

Keywords

Guillain-Barre syndrome
COVID-19
electroneuromyography

How to Cite

Petrova, U., Garmash, Y., Klimenko, O., Bedny, V., Mylnikova, O., & Eagle, V. (2022). CLINICAL CASE OF COVID-ASSOCIATED GUILLAIN-BARRE SYNDROME. Clinical and Preventive Medicine, (1), 44-50. https://doi.org/10.31612/2616-4868.1(19).2022.06

Abstract

The aim of our article is to shed light on the problem of the development of Guillain-Barre syndrome after COVID-19 infection

Materials and methods

The main research methods we used were scientific research and the actual description of our own clinical case. Laboratory research methods, magnetic resonance imaging, and electromyography were used to confirm the diagnosis and perform differential diagnostics.

Results.

In 2021, the Center for Acute Neurology and Pain Treatment treated 12 patients with Guillain-Barre syndrome. Guillain-Barre syndrome (GBS) is an acute autoimmune inflammatory polyradiculoneuropathy. The clinical picture of GBS includes progressive motor and sensory disorders in the extremities and pain.

We bring to your attention a clinical case of GBS in patient B., who was treated at the clinical hospital "Feofania". Patient B., 32 years old, was hospitalized in the Feofania Clinical Hospital with complaints of weakness in her arms and legs, inability to walk, foreign body sensation in the throat, difficulty swallowing, chest discomfort, and difficulty breathing. A few weeks before the disease, the patient was treated for a mild SARS-CoV-2 infection. The patient's condition gradually deteriorated by day 25 of the disease, despite plasmapheresis, intravenous immunoglobulin and glucocorticoid therapy. However, from day 29, the condition gradually improved and on re-examination after 2 months, the patient remained mild distal paresis of the leg muscles (up to 4 points), decreased tendon reflexes from the lower extremities. Disorders of sensitivity and function of the pelvic organs were not observed.

Conclusion.

In our article, we present a case of COVID-19-associated GBS with a classic clinical picture, increased peripheral paresis, stabilization, and gradual recovery of all functions (respiration, pelvic function, motor, sensory, and reflex) through pathogenetic treatment and follow-up rehabilitation measures.

https://doi.org/10.31612/2616-4868.1(19).2022.06
ARTICLE PDF (Українська)

References

Suponeva N.A. (2013). Klynycheskaia i dyahnostycheskaia rol autoantytel k hanhlyozydam peryferycheskykh nervov: obzor lyteraturi y sobstvennie dannie. [Clinical and diagnostic role of autoantibodies to gangliosides of peripheral nerves: literature review and personal data]. Neuromuscular diseases. M.,26-34.

Suponeva N.A., Pyradov M.A., Hryshyna D.A.,. Mochalova E.H. (2014) Effektyvnost patohenetycheskoi terapyy pry syndrome Hyiena – Barre. [The effectiveness of pathogenetic therapy in Guillain-Barré syndrome]. Effective pharmacotherapy. M. ,12-22.

Khrulev A.E., Shyianova N.A., Sorokoumova S.N., Kasatkyn D.S., Hryhoreva V.N., Beliakov K.M., Romanova E.S., Yankevych D.S. (2021) Ostrye y khronycheskye dyzymmunnye polynevropatyy v uslovyiakh pandemyy COVID-19: patohenez, osobennosty klynycheskoi kartyny, dyahnostyky y terapyy (obzor lyteratury). [Acute and chronic dysimmune polyneuropathies in the context of the COVID-19 pandemic: pathogenesis, features of the clinical picture, diagnosis and therapy (literature review). Neuromuscular diseases. M., 17-27.

Abu-Rumeileh, S., Abdelhak, A., Foschi, M., Tumani, H., & Otto, M. (2021). Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of neurology, 268(4), 1133–1170. https://doi.org/10.1007/s00415-020-10124-x

Donofrio P. D. (2017). Guillain-Barré Syndrome. Continuum (Minneapolis, Minn.), 23(5, Peripheral Nerve and Motor Neuron Disorders), 1295–1309. https://doi.org/10.1212/CON.0000000000000513

Hughes, R., Cornblath, D. R., & Willison, H. J. (2016). Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain : a journal of neurology, 139(11), 3041–3047. https://doi.org/10.1093/brain/aww247

Liu, S., Dong, C., & Ubogu, E. E. (2018). Immunotherapy of Guillain-Barré syndrome. Human vaccines & immunotherapeutics, 14(11), 2568–2579. https://doi.org/10.1080/21645515.2018.1493415

Mier-y-Teran-Romero, L., Delorey, M.J., Sejvar, J.J. et al. Guillain–Barré syndrome risk among individuals infected with Zika virus: a multi-country assessment. BMC Med 16, 67 (2018). https://doi.org/10.1186/s12916-018-1052-4

Pritchard, J., Hughes, R. A., Hadden, R. D., & Brassington, R. (2016). Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. The Cochrane database of systematic reviews, 11(11), CD008630. https://doi.org/10.1002/14651858.CD008630.pub4

Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. Lancet (London, England), 388(10045), 717–727. https://doi.org/10.1016/S0140-6736(16)00339-1

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.